Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Clasificación en acciones #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Precio por acción
$59.43
Capitalización bursátil
$121.03B
Cambio (1 día)
0.83%
Cambio (1 año)
0.90%
País
US
Comercio Bristol-Myers Squibb Company (BMY)

Categoría

Ratio P/B de Bristol-Myers Squibb Company (BMY)
Ratio P/B al March 2026 TTM: 6.53
Según los informes financieros más recientes y el precio de las acciones de Bristol-Myers Squibb Company, el ratio P/B actual (TTM) es 6.53. Al final de 2024, el ratio P/B era 7.02.
Historial del ratio P/B de Bristol-Myers Squibb Company desde 2000 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) 6.53 -100.00%
2025 0.00 -100.00%
2024 7.02 94.57%
2023 3.61 -26.89%
2022 4.93 28.08%
2021 3.85 4.03%
2020 3.70 74.59%
2019 2.12 -64.94%
2018 6.05 -29.54%
2017 8.59 42.23%
2016 6.04 -24.90%
2015 8.04 22.05%
2014 6.59 14.22%
2013 5.77 44.33%
2012 4.00 6.41%
2011 3.75 30.06%
2010 2.89 -14.03%
2009 3.36 -10.57%
2008 3.76 -24.09%
2007 4.95 -4.20%
2006 5.16 29.01%
2005 4.00 -17.94%
2004 4.88 -13.85%
2003 5.66 7.21%
2002 5.28 -51.57%
2001 10.90 -27.65%
2000 15.07 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
33.3372 410.72%
US
6.0657 -7.07%
GB
7.1931 10.20%
US
-119.6075 -1,932.36%
US
6.3334 -2.97%
CH